On April 2, Yunnan Baiyao Group Co.Ltd(000538) released the minutes of the investor research meeting, which lost nearly 2 billion yuan in stock speculation in 2021. According to the announcement, in terms of securities investment, Yunnan Baiyao Group Co.Ltd(000538) will gradually reduce its positions and no longer increase its holdings in 2022.
In 2021, Yunnan Baiyao Group Co.Ltd(000538) achieved a revenue of 35.374 billion yuan, with a year-on-year increase of 11.09%; The net profit attributable to shareholders of listed companies was 280 million yuan, down 49.17% year-on-year, the first year-on-year decline in 20 years. The profit and loss from changes in fair value in stock speculation alone reached 1.981 billion yuan in the current period Yunnan Baiyao Group Co.Ltd(000538) among the nine stocks invested by Xiaomi group, Tencent holdings, Inner Mongolia Yili Industrial Group Co.Ltd(600887) , Jiangsu Hengrui Medicine Co.Ltd(600276) , Xiaomi group, Jiangsu Hengrui Medicine Co.Ltd(600276) and Tencent holdings lost the most, with RMB 1.404 billion, RMB 220 million and RMB 134 million respectively. In 2020, Yunnan Baiyao Group Co.Ltd(000538) once earned more than 2.2 billion yuan through stock speculation.
According to the dividend plan issued by Yunnan Baiyao Group Co.Ltd(000538) company, the "red envelope" distributed by Yunnan Baiyao Group Co.Ltd(000538) company also shrank. From 2010 to 2020, the cash dividends distributed by Yunnan Baiyao Group Co.Ltd(000538) increased year by year. Among them, before 2017, the cash dividend distributed per 10 shares was less than 6 yuan (inclusive), and in 2017, the cash dividend distributed per 10 shares increased to 15 yuan. The cash dividends distributed per 10 shares in 2018, 2019 and 2020 were 20 yuan, 30 yuan and 39 yuan respectively, without bonus shares. In 2021, the cash dividend for every 10 shares will be reduced to 16 yuan, but 4 bonus shares will be given.
Previously, Shanghai Raas Blood Products Co.Ltd(002252) also vowed not to touch stocks because of huge losses in stock speculation. In 2018, Shanghai Raas Blood Products Co.Ltd(002252) due to the loss of more than 1.1 billion yuan in stock speculation, the net profit attributable to the parent company in that year was a huge loss of -1.518 billion yuan Shanghai Raas Blood Products Co.Ltd(002252) then announced that it would no longer participate in new securities investment, and the original securities investment would gradually withdraw. In the future, it would no longer carry out securities investment, focusing on the development of the main business of blood products and biological products related industries.
Yunnan Baiyao Group Co.Ltd(000538) huge losses in stock speculation also attracted investors' attention. In the investor research teleconference held on April 1, Sinolink Securities Co.Ltd(600109) asked about Yunnan Baiyao Group Co.Ltd(000538) 2022's securities investment plan. In this regard, Yunnan Baiyao Group Co.Ltd(000538) said that it would fully listen to the opinions and suggestions of the majority of investors on the development of the company, strictly control the investment scale of the secondary market on the basis of the original risk control measures, and gradually reduce the position within the limit approved by the board of directors in 2022.
For strategic positioning, Yunnan Baiyao Group Co.Ltd(000538) in response to investors, said that it would focus on the development and transformation of the "1 + 4 + 1" strategy, that is, deeply cultivate the development in the field of traditional Chinese medicine, and layout the product matrix in the four fields of oral cavity, skin, bone injury and female care, focusing on drugs, including various forms of drugs, traditional Chinese medicine, innovative drugs, biological drugs, etc., as well as equipment and food, from prevention to detection, treatment to rehabilitation, Make corresponding product layout. At the same time, the digital technology based on artificial intelligence is introduced into all links of R & D and operation.
